Erratum: Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China [Corrigendum].

[This corrects the article DOI: 10.2147/CMAR.S249153.].

Peng W, Zhang F, Wang Z, et al. Cancer Manag Res. 2020;12:6977—6985.

Page 6980, Effectiveness, second paragraph, last sentence, the text “In third-line and above, the DCR was 81.82% vs 76.59% with no significant difference between the two treatment groups (Table 2)” should read “In third-line and above, the DCR was 74.23% vs 81.82% with no significant difference between the two treatment groups (Table 2)”.

Table 2 Response of Patients to Monotherapy and Combination Therapy in Different Treatment Lines

Response	F-A (n=88)	F-C (n=140)	P value	S-A (n=81)	S-C (n=63)	P value	T-A (n=97)	T-C (n=44)	P value
CR	1(1.1%)	3(2.1%)	-	0(0%)	0(0%)	-	0(0%)	0(0%)	-
PR	7(8.0%)	20(14.3%)	-	10(12.3%)	6(9.5%)	-	4(4.1%)	0(0%)	-
SD	61(69.3%)	102(72.9%)	-	57(70.4%)	47(74.6%)	-	68(70.1%)	36(81.8%)	-
PD	19(21.6%)	15(10.7%)	-	14(17.3%)	10(15.9%)	-	25(25.8%)	8(18.2%)	-
ORR(95% CI)	9.09%(4.01-17.13)	16.42% (10.71-23.62)	0.167	12.35% (6.08-21.53)	9.52% (3.58-19.59)	0.632	4.12% (1.13-10.22)	0%	0.315
DCR(95% CI)	78.41% (68.35-86.47)	89.29% (82.94-93.88)	0.521	82.72% (72.70-90.22)	84.13% (72.74-92.12)	0.946	74.23% (64.35-82.58)	81.82% (67.29-91.81)	0.722

The data in Table 2 on page 6980 is incorrect. The correct Table 2 is shown below.

The authors apologize for these errors and advise they do not affect the results of the paper.